[영문]OBJECTIVE: To review the metabolic syndrome as defined by the 2001 Expert Panelon Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III)and its modifiable risk factors and to review currently available treatment modalities.SUMMARY: Metabolic syndrome, although still controversial, is a growing concern.Most definitions include elevated blood pressure, smoking, inflammation, insulinresistance, abdominal adiposity, elevated blood glucose, and atherogenic dyslipidemiaas modifiable risk factors. Some researchers believe that additional signsof inflammation such as plasminogen activator inhibitor-1 and C-reactive proteinshould be added to this list. Current treatment options include lifestyle changes (dietand exercise), pharmacotherapy, and bariatric surgery. The endocannabinoid systemappears to play a key role in metabolism and weight gain. The investigational agentrimonabant is a cannabinoid receptor type 1 blocker that has been employed innumerous trials involving more than 6,500 patients. It has led to significant weightloss, reduced central fat, and improved glycemic and lipid profiles.